The dramatic growth in TAVR was based initially on its application in patients believed to be either high risk or inoperable for surgical aortic valve replacement. These high-risk features include advanced age and multiple comorbidities, the latter of which often make long-term anticoagulation (AC) problematic. The goals of TAVR in this population include documented survival benefit in some subsets, reduction in hospitalizations for congestive heart failure, and, perhaps most important, an improvement in quality of life.
Although TAVR demonstrated a survival benefit, there was a higher than expected incidence of disabling post-procedural and follow-up strokes, especially with the first-generation devices. Potential mechanisms include embolization from the aorta, the native valve, and/or the left atrial appendage, as well as periprocedural interruption of antithrombotic agents in patients with AF. Since those early studies, intense research has been directed at reducing the risk for stroke. Reduction in the size of delivery systems has helped. In addition, ongoing studies are evaluating the role of embolic protection carotid filters during the procedure.
AF has also generated great interest because it is the most common significant arrhythmia, it is associated with increasing age, and it plays a central role in the etiology of stroke in older patients (4, 5) . Specifically, nonvalvular AF has been believed to be the putative mechanism of stroke in at least 20% of older patients.
Although AC has been studied intensively and has been found to decrease stroke rates, it is underused, often because of bleeding concerns (6) . For these issues, local site-specific treatment strategies have been 
